Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New rabies vaccine shows promise in large trial

NCT ID NCT04127786

First seen Feb 13, 2026 · Last updated Jun 22, 2026 · Updated 18 times

Summary

This Phase 3 trial tested a new rabies vaccine (VRVg-2) in 1708 healthy children and adults in Thailand. The goal was to see if it works as well as two existing rabies vaccines when given before exposure to the virus. Participants received a series of shots, and some got a booster dose later. The study is complete, and results will show if the new vaccine is a safe and effective option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Investigational Site Number : 7640001

    Bangkok, 10330, Thailand

  • Investigational Site Number : 7640002

    Khon Kaen, 40002, Thailand

  • Investigational Site Number : 7640003

    Bangkok, 10700, Thailand

  • Investigational Site Number : 7640004

    Bangkok, 10400, Thailand

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Purified vero rabies vaccine - serum free (VRVg-2)

What this could lead to

If successful, this could provide a safe and effective alternative rabies vaccine for pre-exposure prevention in both children and adults.

What could go wrong

This is a completed Phase 3 trial, but results are not yet published. The new vaccine must prove it is as good as existing ones, and rare side effects may still emerge.

Conditions

The condition(s) this trial relates to.

rabies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.